Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Thrombosis platelets

During thrombosis platelets adhere to blood vessel walls and aggregate to form a blood clot or thrombus. Platelet aggregation is dependent on the intraplatelet Ca2 + concentration. Nitric oxide is able to inhibit thrombosis by indirectly decreasing... [Pg.247]

An intact endothelium acts as a physical barrier to platelets adhesion. 4s well as causing vessel thrombosis, platelets produce factors that stimulate smooth muscle cells, leading to restenosis. [Pg.356]

They must have high oxygen and carbon dioxide permeability. They should be chemically stable without leachable moieties and be blood compatible, minimizing thrombosis, platelet activation and injury, and protein denaturation. [Pg.157]

Thrombosis (platelet activation, aggregation, and deposition at the vascular injury site)... [Pg.692]

Uric acid activates clotting Factor XII and hyperuricaemia in rats is associated with increased platelet aggregation (l) with increased adenosine diphosphate-induced pulmonary platelet thrombosis. Platelet survival is decreased and platelet turnover correspondingly increased in some primary gout patients and this abnormality is reversed during uricosuric therapy with sulfinpyrazone (2,3) ... [Pg.159]

Homocysteine arises from dietary methionine. High levels of homocysteiae (hyperhomocysteinemia) are a risk factor for occlusive vascular diseases including atherosclerosis and thrombosis (81—84). In a controlled study, semm folate concentrations of <9.2 nmol/L were linked with elevated levels of plasma homocysteiae. Elevated homocysteine levels have beea associated also with ischemic stroke (9). The mechanism by which high levels of homocysteine produce vascular damage are, as of yet, aot completely uaderstood. lateractioa of homocysteiae with platelets or eadothehal cells has beea proposed as a possible mechanism. Clinically, homocysteine levels can be lowered by administration of vitamin B, vitamin B 2> foHc acid. [Pg.42]

In general, arterial thrombi are platelet-rich ( white clots ) and form at ruptured atherosclerotic plaques, leading to intraluminal occlusion of arteries that can result in end-organ injury (e.g., myocardial infarction, stroke). In contrast, venous thrombi consist mainly of fibrin and red blood cells ( red clots ), and usually form in low-flow veins of the limbs, producing deep vein thrombosis (DVT) the major threat to life results when lower extremity (and, occasionally, upper extremity) venous thrombi embolize via the right heart chambers into the pulmonary arteries, i.e., pulmonary embolism (PE). [Pg.108]

Platelets play a central role in primary hemostasis. They are also important in pathological processes leading to thrombosis. Antiplatelet drugs are primarily directed against platelets and inhibit platelet activation by a number of different mechanisms. They are used for the prevention and treatment of thrombotic processes, especially in the arterial vascular system. [Pg.167]

Due to the pivotal role of platelets in thrombus formation, especially in the arterial system, inhibition of platelet function has become a central pharmacological approach. Antiplatelet drugs are given in order to prevent and treat thromboembolic diseases such as coronary heart disease, peripheral and cerebrovascular disease. They have also revolutionized the procedures of invasive coronary interventions as they reduce the risk of restenosis and thrombosis. [Pg.170]

Aspirin has been remarkably successful in the treatment of the pain and swelling of inflammatory disease and in fact, an estimated 45,000 tons of aspirin are still consumed each year. This success resulted in the syntheses of many other aspirin-like drugs , now referred to as NSAIDs. Aspirin, however, continues to have a unique use in the prevention of thrombosis. Since it produces irreversible inhibition of COX-1 by acetylation of serine at position 530 in the active site, a daily low dose of aspirin will cause a cumulative inhibition of COX-1 in platelets, in the portal circulation. A gradual inhibition of platelet aggregation occurs, reducing the possibility of occlusion of coronary or cerebral vessels by platelet thrombi. However, there are no systemic... [Pg.404]

Thrombosis is the development of a thrombus , consisting of platelets, fibrin, red and white blood cells in the arterial or venous circulation. Platelet-rich white thrombi are found in the arterial system and can be prevented by antiplatelet drugs. [Pg.1200]

Hemostasis is the cessation of bleeding from a cut or severed vessel, whereas thrombosis occurs when the endothelium lining blood vessels is damaged or removed (eg, upon rupmre of an atherosclerotic plaque). These processes encompass blood clotting (coagulation) and involve blood vessels, platelet aggregation, and plasma proteins that cause formation or dissolution of platelet aggregates. [Pg.598]

We shall first describe the coagulation pathway leading to the formation of fibrin. Then we shall briefly describe some aspects of the involvement of platelets and blood vessel walls in the overall process. This separation of clotting factors and platelets is artificial, since both play intimate and often mutually interdependent roles in hemostasis and thrombosis, but it facifitates description of the overall processes involved. [Pg.598]

Hemostasis and thrombosis are complex processes involving coagulation factors, platelets, and blood vessels. [Pg.608]

Roth GJ, Calverley DC Aspirin, platelets, and thrombosis theory and practice. Blood 1994 83 885. [Pg.608]

Junghans U, Seitz RJ, Wittsack HJ, Aulich A, Siebler M. Treatment of acute basilar artery thrombosis with a combination of systemic alteplase and tirofiban, a nonpeptide platelet glycoprotein Ilb/HIa inhibitor report of four cases. Radiology 2001 221 795-801. [Pg.116]

Early studies indicate that combined GP Ilb/IIIa inhibition with rt-PA thrombolysis may improve clinical and MRI outcomes after acute ischemic stroke, with an acceptable safety prohle. The dual targeting of platelets and hbrin by combination therapy may provide synergistic benefits, including increased arterial recanalization, reduced microvascular thrombosis, reduced arterial reocclusion, and less rt-PA-mediated blood-brain barrier injury and secondary activation of the coagulation system. [Pg.147]

Convert to oral warfarin pharmacotherapy once the platelet count has returned to baseline values (preferably >100-150 x 109/L). Continue for at least 30 d in patients without evidence of thrombosis (optimal duration is not known but one author recommends at least 2-3 mo of warfarin Blood, 2003). Continue for at least 6 mo in patients with evidence... [Pg.122]

Describe the processes of hemostasis and thrombosis, including the role of the vascular endothelium, platelets, coagulation cascade, and thrombolytic proteins. [Pg.133]

The ACCP Conference on Antithrombotic Therapy recommended against the use of aspirin as the primary method of VTE prophylaxis.2 Antiplatelet drugs clearly reduce the risk of coronary artery and cerebrovascular events in patients with arterial disease, but aspirin produces a very modest reduction in VTE following orthopedic surgeries of the lower extremities. The relative contribution of venous stasis in the pathogenesis of venous thrombosis compared with that of platelets in arterial thrombosis likely explains the reason for this difference. [Pg.141]

The advent of COX-2-selective inhibitors has led to unexpected results. By selectively inhibiting the COX-2 isoform, COX-2-selective NSAIDs increase the risk of cardiovascular events in certain patientsP COX-2 is responsible for the production of prostacyclin, a vasodilatory and antiplatelet substance. On the other hand, COX-1 controls the production of thromboxane A2, a vasoconstrictor and platelet aggregator. Selective inhibition of COX-2 results in decreased prostacyclin levels in the face of stable thromboxane A2 levels. An imbalance in the thromboxane A2 prostacyclin ratio ensues, which creates an environment that favors thrombosis. [Pg.886]


See other pages where Thrombosis platelets is mentioned: [Pg.352]    [Pg.347]    [Pg.193]    [Pg.31]    [Pg.460]    [Pg.521]    [Pg.56]    [Pg.352]    [Pg.347]    [Pg.193]    [Pg.31]    [Pg.460]    [Pg.521]    [Pg.56]    [Pg.386]    [Pg.10]    [Pg.78]    [Pg.112]    [Pg.145]    [Pg.145]    [Pg.169]    [Pg.225]    [Pg.228]    [Pg.637]    [Pg.866]    [Pg.197]    [Pg.418]    [Pg.598]    [Pg.602]    [Pg.607]    [Pg.78]    [Pg.166]    [Pg.101]    [Pg.135]    [Pg.137]    [Pg.996]   
See also in sourсe #XX -- [ Pg.3 ]




SEARCH



Coronary arteries platelet thrombosis inhibition

Coronary thrombosis, platelet-dependent

Platelet aggregation arterial thrombosis due

Platelet coronary artery thrombosis

Platelets and thrombosis

Thrombosis

© 2024 chempedia.info